AU2015246036A1 - S1P modulator immediate release dosage regimen - Google Patents

S1P modulator immediate release dosage regimen Download PDF

Info

Publication number
AU2015246036A1
AU2015246036A1 AU2015246036A AU2015246036A AU2015246036A1 AU 2015246036 A1 AU2015246036 A1 AU 2015246036A1 AU 2015246036 A AU2015246036 A AU 2015246036A AU 2015246036 A AU2015246036 A AU 2015246036A AU 2015246036 A1 AU2015246036 A1 AU 2015246036A1
Authority
AU
Australia
Prior art keywords
siponimod
day
dosage form
patient
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2015246036A
Other languages
English (en)
Inventor
Philippe Michael Rene BOUILLOT
Frank Dahlke
Eric Legangneux
Emeric Reynaud
Erik Wallstroem
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52988364&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2015246036(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2015246036A1 publication Critical patent/AU2015246036A1/en
Priority to AU2020203107A priority Critical patent/AU2020203107B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2015246036A 2014-04-10 2015-04-08 S1P modulator immediate release dosage regimen Abandoned AU2015246036A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020203107A AU2020203107B2 (en) 2014-04-10 2020-05-12 S1P modulator immediate release dosage regimen

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461977816P 2014-04-10 2014-04-10
US61/977,816 2014-04-10
PCT/IB2015/052550 WO2015155709A1 (en) 2014-04-10 2015-04-08 S1p modulator immediate release dosage regimen

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020203107A Division AU2020203107B2 (en) 2014-04-10 2020-05-12 S1P modulator immediate release dosage regimen

Publications (1)

Publication Number Publication Date
AU2015246036A1 true AU2015246036A1 (en) 2016-10-13

Family

ID=52988364

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2015246036A Abandoned AU2015246036A1 (en) 2014-04-10 2015-04-08 S1P modulator immediate release dosage regimen
AU2020203107A Active AU2020203107B2 (en) 2014-04-10 2020-05-12 S1P modulator immediate release dosage regimen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020203107A Active AU2020203107B2 (en) 2014-04-10 2020-05-12 S1P modulator immediate release dosage regimen

Country Status (16)

Country Link
US (4) US20170027907A1 (https=)
EP (3) EP4074312B1 (https=)
JP (1) JP6674903B2 (https=)
KR (2) KR20160141841A (https=)
CN (2) CN106456552A (https=)
AU (2) AU2015246036A1 (https=)
CA (1) CA2943598C (https=)
CL (1) CL2016002562A1 (https=)
IL (2) IL305337A (https=)
MX (1) MX2016013245A (https=)
PH (1) PH12016501965A1 (https=)
RU (2) RU2715734C2 (https=)
SG (1) SG11201607894RA (https=)
TW (1) TW201622721A (https=)
WO (1) WO2015155709A1 (https=)
ZA (1) ZA201606519B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2699580T3 (https=) 2014-01-24 2018-02-24
MX2016013245A (es) * 2014-04-10 2017-01-16 Novartis Ag Regimen de dosificacion de liberacion inmediata de moduladores s1p.
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
MX2020007268A (es) * 2017-09-29 2020-08-17 Novartis Ag Regimen de dosificacion de siponimod.
AU2018343239A1 (en) * 2017-09-29 2020-03-12 Novartis Ag Dosing regimen of siponimod
KR20250002710A (ko) * 2018-03-01 2025-01-07 아스트라제네카 에이비이 (2s)-n-｛(1s)-1-시아노-2-[4-(3-메틸-2-옥소-2,3-디하이드로-1,3-벤족사졸-5-일)페닐]에틸｝-1,4-옥사제판-2-카복스아미드를포함하는 약학 조성물
AU2019306532A1 (en) 2018-07-17 2021-03-04 Insmed Incorporated Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating Lupus Nephritis
CN109908095A (zh) * 2019-04-08 2019-06-21 肇庆学院 一种西尼莫德片剂及制备方法
AU2020372647B2 (en) 2019-10-31 2026-02-05 Idorsia Pharmaceuticals Ltd Combination of a CXCR7 antagonist with an S1P1 receptor modulator
WO2021158838A1 (en) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Dosage regimen of an s1p receptor modulator
EP4646265A1 (en) 2023-01-06 2025-11-12 Insmed Incorporated Novel, reversible dpp1 inhibitors and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2676953T (pt) * 2008-12-18 2017-06-29 Novartis Ag Sal hemifumarato de ácido 1-[4-[1-(4-ciclo-hexil-3-trifluorometil-benziloxi-imino)-etil]-2-etil-benzil]-azetidino-3-carboxílico para utilização no tratamento de doenças mediadas por linfócitos
CN105213372A (zh) 2008-12-22 2016-01-06 诺华股份有限公司 S1p受体激动剂的给药方案
RS66784B9 (sr) * 2008-12-22 2025-08-29 Novartis Ag Režim doziranјa agonista s1p receptora
EP2482810A2 (en) * 2009-09-29 2012-08-08 Novartis AG Dosage regimen of an s1p receptor modulator
BR112013017302B1 (pt) * 2011-01-07 2021-12-07 Novartis Ag Composição farmacêutica em fase sólida
WO2012095853A1 (en) * 2011-01-10 2012-07-19 Novartis Pharma Ag Modified release formulations comprising sip receptor modulators
PH12014500854A1 (en) * 2011-10-21 2021-08-09 Novartis Ag Dosage regimen for an s1p receptor modulator or agonist
MX2016013245A (es) * 2014-04-10 2017-01-16 Novartis Ag Regimen de dosificacion de liberacion inmediata de moduladores s1p.

Also Published As

Publication number Publication date
EP4074312B1 (en) 2026-02-25
PH12016501965A1 (en) 2017-01-09
IL305337A (en) 2023-10-01
AU2020203107A1 (en) 2020-05-28
EP3129020A1 (en) 2017-02-15
CN106456552A (zh) 2017-02-22
US20170027907A1 (en) 2017-02-02
AU2020203107B2 (en) 2021-10-21
US20190054065A1 (en) 2019-02-21
EP3831378A1 (en) 2021-06-09
JP6674903B2 (ja) 2020-04-01
RU2016143979A3 (https=) 2018-11-12
KR20220156981A (ko) 2022-11-28
RU2715734C2 (ru) 2020-03-03
SG11201607894RA (en) 2016-10-28
RU2020107732A (ru) 2020-03-30
CA2943598A1 (en) 2015-10-15
CL2016002562A1 (es) 2017-07-28
WO2015155709A1 (en) 2015-10-15
US20220016076A1 (en) 2022-01-20
JP2017510607A (ja) 2017-04-13
IL247986A0 (en) 2016-11-30
EP4074312C0 (en) 2026-02-25
US20250041266A1 (en) 2025-02-06
TW201622721A (zh) 2016-07-01
KR20160141841A (ko) 2016-12-09
EP4074312A1 (en) 2022-10-19
ZA201606519B (en) 2017-11-29
CA2943598C (en) 2023-03-07
MX2016013245A (es) 2017-01-16
RU2016143979A (ru) 2018-05-14
CN116650467A (zh) 2023-08-29

Similar Documents

Publication Publication Date Title
US20250041266A1 (en) S1p modulator immediate release dosage regimen
TWI632909B (zh) 治療阿滋海默症之方法以及其醫藥組成物
US12161758B2 (en) Modified release formulations and uses thereof
CN117137912A (zh) 选择性s1p1受体激动剂的给药方案
US12533340B2 (en) Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
HK40053433A (en) Siponimod immediate release dosage regimen for treating autoimmune diseases
HK40081576A (en) Siponimod immediate release dosage regimen for treating autoimmune diseases
CA3105680A1 (en) Treatment of the pruritic symptoms of liver disease
CA2973540C (en) Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
TW202527911A (zh) 用於治療猝睡症的化合物
CN117715621A (zh) 三峰、精确定时的脉冲释放片剂
TW202237084A (zh) 修飾釋放調配物及其用途

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted